PolyPid (PYPD) Non-Current Assets (2019 - 2026)
PolyPid (PYPD) posted Non-Current Assets of $6.6 million for Q1 2026, down 6.78% sequentially from $7.1 million in Q4 2025, and down 18.29% YoY from $8.1 million in Q1 2025.
PolyPid (PYPD) Non-Current Assets (2019 - 2026) Analysis & Trends
PolyPid has reported Non-Current Assets for 8 years, with the latest figure at $6.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 18.29% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (down 18.29% YoY) and the FY2025 annual result came in at $7.1 million, down 18.12% from the prior year.
- Non-Current Assets slipped to $6.6 million in Q1 2026 per PYPD's latest filing, from $7.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $11.8 million in Q4 2022 and troughed at $6.6 million in Q1 2026.
- A 5-year average of $9.2 million and a median of $9.6 million in 2022 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 24.97% in 2022, down 47.14% in 2022.
- Over 5 years, Non-Current Assets stood at $11.8 million in 2022, then slipped by 20.99% to $9.3 million in 2023, then slipped by 7.07% to $8.6 million in 2024, then slipped by 18.12% to $7.1 million in 2025, then slipped by 6.78% to $6.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $6.6 million, $7.1 million, and $7.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | 6.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.35 Mn |
| Mar 31, 2026 | 6.60 Mn |
| Dec 31, 2025 | 7.08 Mn |
| Sep 30, 2025 | 7.26 Mn |
| Jun 30, 2025 | 7.70 Mn |
| Mar 31, 2025 | 8.08 Mn |
| Dec 31, 2024 | 8.65 Mn |
| Sep 30, 2024 | 9.15 Mn |
| Jun 30, 2024 | 9.75 Mn |
| Mar 31, 2024 | 10.30 Mn |
| Dec 31, 2023 | 9.31 Mn |
| Sep 30, 2023 | 9.81 Mn |
| Jun 30, 2023 | 10.51 Mn |
| Mar 31, 2023 | 11.11 Mn |
| Dec 31, 2022 | 11.78 Mn |
| Sep 30, 2022 | 9.58 Mn |
| Jun 30, 2022 | 9.80 Mn |
| Mar 31, 2022 | 9.99 Mn |
| Dec 31, 2021 | 9.42 Mn |
| Sep 30, 2021 | 8.14 Mn |